chapter Bone Density (Densitometry) RADIOPHARMACY INDICATIONS Radionuclide Localization Quality Control Adult Dose Range Method of Administration

Similar documents
Bone Densitometry. What is a Bone Density Scan (DXA)? What are some common uses of the procedure?

Interpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm

Osteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.

The Osteoporosis Center at St. Luke s Hospital

John J. Wolf, DO Family Medicine

EXAMINATION CONTENT SPECIFICATIONS ARRT BOARD APPROVED: JANUARY 2017 IMPLEMENTATION DATE: JULY 1, 2017

STRUCTURED EDUCATION REQUIREMENTS IMPLEMENTATION DATE: JULY 1, 2017

Bone Densitometry. Dr. Tudor H. Hughes M.D., FRCR Department of Radiology University of California School of Medicine San Diego, California

Bone Mineral Densitometry with Dual Energy X-Ray Absorptiometry

My joints ache. What is the difference between osteoporosis and osteoarthritis?

OSTEOPOROSIS ASSESSMENT CENTER

Osteoporosis: Risk Factors, Diagnostic Methods And Treatment Options

Bone Densitometry. Total 30 Maximum CE 14. DXA Scanning (10) 7

The Bone Densitometry Examination

Osteoporosis. Skeletal System

AACE/ACE Osteoporosis Treatment Decision Tool

Objectives. Discuss bone health and the consequences of osteoporosis on patients medical and disability status.

Osteoporosis/Fracture Prevention

1

Building Bone Density-Research Issues

Accuracy of DEXA scanning & other methods for determining BMD.

Osteoporosis and Lupus. Andrew Ruthberg, MD University Rheumatologists

Guideline for the investigation and management of osteoporosis. for hospitals and General Practice

DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi

LUMBAR IS IT IMPORTANT? S. Tantawy,, M.D.

SOUTH TEXAS FRACTURE PREVENTION CLINIC PRE-DEXA PATIENT QUESTIONNAIRE

Cortical bone After age 40, gradually decreases % yearly, in both men and women Postmenopausally, loss accelerates to 2-3% yearly

Prevalence of Osteoporosis p. 262 Consequences of Osteoporosis p. 263 Risk Factors for Osteoporosis p. 264 Attainment of Peak Bone Density p.

Bone Mineral Density Studies in Adult Populations

Osteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011

Medical Review. The following slides were medically reviewed by Dr. Nancy Dawson in June 2018.

Thank you for calling the Osteoporosis Assessment Center to schedule your DEXA (bone mineral density study) appointment on.

Use of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist

Osteoporosis. Treatment of a Silently Developing Disease

What is Osteoporosis?

Bone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008

Horizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre

InfoSheet Osteoporosis

Bone Densitometry Pathway

Bone density scanning and osteoporosis

Osteoporosis. Definition

Breast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime

Autonomic neuropathy

The Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD

Skeletal Manifestations

Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital

A Patient s Guide to Osteoporosis

Contractor Number 03201

Objectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING

Osteoporosis challenges

Osteoporosis Management

Osteoporosis in Men Wendy Rosenthal PharmD. This program has been brought to you by PharmCon

Adrenocortical Scan. Quality Control. Adult Dose Range

Vasu Pai FRACS, Nat Board, MCh, M.S

Parathyroid Hormone Analogs

Prevalence of Osteoporosis 5/3/2017. Rhiannon Anderson, PA-C, FLS Linda Mitchell, PA-C, FLS, DEXA Specialist

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

Osteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK

New 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS

MEASURE. MANAGE. MOTIVATE. bodyandbone MOBILE LAB DEXA BODY COMPOSITION SCAN RESTING METABOLIC RATE TEST DEXA BONE MINERAL DENSITY TEST

2013 ISCD Official Positions Adult

Index. Rheum Dis Clin N Am 32 (2006) Note: Page numbers of article titles are in boldface type.

Chapter 39: Exercise prescription in those with osteoporosis

Osteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018

OSTEOPOROSIS MANAGEMENT AND INVESTIGATION. David A. Hanley, MD, FRCPC

Page 1

Practical Management Of Osteoporosis

COURSE OUTLINE - Module I

Osteoporosis Agents Drug Class Prior Authorization Protocol

Clinician s Guide to Prevention and Treatment of Osteoporosis

Osteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis

BONE HEALTH AND HIV DISEASE. information on how to prevent and treat osteopenia and osteoporosis

Corporate Medical Policy

F REQUENTLY A SKED Q UESTIONS. Osteoporosis

Bone Densitometry Equipment Operator

Englewood Orthopedic Associates 401 South Van Brunt Street Englewood, NJ Tel: Fax: Jessica Fleischer, MD

Initial Pathway for DEXA Referral and Treatment for Fracture Risk Reduction in Postmenopausal Women and Men Age 50 or Above

DISUSE OSTEOPOROSIS IN PATIENTS WITH POLIOMYELITIS

BONIVA (ibandronate sodium)

OSTEOPOROSIS: AN OPPORTUNITY OR OBLIGATION

Prevention of Osteoporotic Hip Fracture

Osteoporosis. Osteoporosis ADD PICTURE

FORTEO (teriparatide) INJECTION

To understand bone growth and development across the lifespan. To develop a better understanding of osteoporosis.

Section 4. Scans and tests. How do I know if I have osteoporosis? Investigations for spinal fractures. Investigations after you break a bone

Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis

Adina Alazraki, MD, FAAP Assistant Professor, Radiology and Pediatrics Emory University School of Medicine Children s Healthcare of Atlanta

Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio

Osteoporosis. Overview

Osteoporosis: Who, What, When, Why, and How

Major Recommendations Recommendations apply to postmenopausal women and men age 50 and older.

LOVE YOUR BONES Protect your future

OSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO

Fragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey

All about. Osteoporosis

TYMLOS (abaloparatide)

OSTEOPOROSIS DR ANAHITA BABAK COMMUNITY AND PREVENTIVE MEDICINE SPECIALIST

Foreword...v Preface...vii Acknowledgments... xi Dedication... xiii Continuing Medical Education... xxv. Chapter 1: Densitometry Techniques...

Dumfries and Galloway. Treatment Protocol for Osteoporosis

Introduction with terms of use agreement

Transcription:

10766-04_CH04_redo.qxd 12/3/07 3:47 PM Page 17 chapter 4 Bone Density (Densitometry) RADIOPHARMACY Radionuclide Single radionuclide: 125 I t 1/2 : 60.1 days Energies: 23 31 kev Type: EC, x, γ, accelerator or: 241 Am (americium) t 1/2 : 432.7 years Energies: 60 kev Type: α, γ, spontaneous fission product. Dual radionuclide: 153 Gd (gadolinium) t 1/2 : 241.6 days Energies: 44, 100 kev (γ); 35, 70 kev (x-ray) Type: x, γ, neutron irradiation of 152 Gd Radiopharmaceutical N/A Localization N/A Quality Control Image phantom every day of use. Adult Dose Range N/A Method of Administration Exposure to, not administration by injection. INDICATIONS Detection of osteoporosis. Monitoring and evaluation of treatment programs for osteoporosis (e.g., estrogen, progesterone, testosterone replacement, calcitonin therapy, exercise, or pharmacologic interventions with vitamins). Evaluation of osteopenia (diminished bone tissue). Evaluation of effect of menopause and premature spontaneous menopause on bone density (for hormone therapy management). Evaluation for premenopausal oophorectomy. Evaluation of effect of steroid therapy on bone density. 17

10766-04_CH04_redo.qxd 12/3/07 3:47 PM Page 18 NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference Evaluation of effect of Cushing s syndrome on bone density (and other endocrinopathies, e.g., prolactinoma, hyperparathyroidism, hyperthyroidism, and male hypogonadism). Detection and evaluation of pathologic fractures. Evaluation of effect of chronic renal disease on bone density. Evaluation of effect of gastrointestinal syndromes on bone density. Evaluation of effect of postgastrectomy and other malabsorption diseases on bone density. Evaluation of effect of long-term immobilization on bone density. Evaluation of bone density due to abnormal results on related studies. CONTRAINDICATIONS Dense vertebrae from degenerative disease, fracture, injury, or metastatic cancer should be excluded as area of interest. Nuclear medicine scan within 7 days of bone density scan. PATIENT PREPARATION Identify the patient. Verify doctor s order. Explain the procedure. Remove metal objects from person and/or pockets. EQUIPMENT Camera Rectilinear-style scanner Bone densitometer single or dual energy x-ray absorptiometry Computer Set-up Factory settings Collimator Collimated x-ray pencil beam PROCEDURE (TIME: ~30 60 MINUTES) SPA (single photon absorptiometry) is suggested in pediatric through adolescent patients because long bones are most metabolically active. It is useful in determining bone development in many childhood and pediatric diseases. There is also SEXA (single energy x-ray absorptiometry), which is more expensive but does not require replacement of the gamma source. Position patient s region of interest (ROI) under the scanner. The denser the bone, the more absorption of photons. Image patient s nondominant arm unless there is a known fracture to that extremity. Because of the low energy of 125I, it is used mainly on wrist or distal forearm studies. (The junction of the middle and distal third of the radius is the preferred site.) Most scanners have preprogrammed scan lengths and processing. Compare results with database table for that patient (usually contained in a software processing program). DPA (dual photon absorptiometry of gamma rays, 20- to 40-minute scan) or DEXA (dual energy x-ray absorptiometry, 2- to 5-minute scan) for other patients emphasizes lumbar spine and proximal femur at the hip. Position patient supine on imaging table; elevate legs at knees to flatten pelvis and lumbar spine against scanning table. Obtain scan of L1 L5, rectilinear fashion, with dual energy photon beam beneath table. Gamma or x-rays pass through patient and are picked up by detector on C-arm above the table. 18

10766-04_CH04_redo.qxd 12/3/07 3:47 PM Page 19 Chapter 4 Bone Density (Densitometry) Obtain scan of proximal femur (hip area). Obtain scan of distal radius and/or wrist. Compare values to those of a database established for patient s characteristics (e.g., age, sex, race, and weight). NORMAL RESULTS Values obtained from scan or scans fall within normal limits listed in established database table. Results are compared with age-matched controls (Z score) or to a young normal population (T score) that represents the peak bone mass. This is expressed as percentages or standard deviations from the normal range. T score of greater (less negative) than 1.0 (<1 standard deviation below young normal controls) is normal. ABNORMAL RESULTS Values between 1.0 and 2.5 are evidence of osteopenia. Values of less (more negative) than 2.5 are osteoporosis. Values 10% lower than published mean for patient s age are considered mildly osteoporotic. Clinically significant osteopenia. Patients with vertebral values between 0.8 and 0.99 g/cm 2 have about a 20% predictability of spontaneous fracture. Patients with vertebral values between 0.62 and 0.8 g/cm 2 are more likely to have a spontaneous fracture. Patients with vertebral values < 0.62 g/cm 2 will be found to have already had at least one spontaneous fracture 100% of the time. ARTIFACTS Overlying metal objects will cause falsely elevated results. A dense vertebra from severe degenerative disease or fracture, injury, or metastatic cancer should not be used for analysis. Degenerative disease with severe facet sclerosis may result in artificially high values. A heavily calcified overlying aorta may result in artificially high values. Recent gastrointestinal barium studies may interfere because of attenuation of the photons by barium. For patients approaching 300 pounds, because of the weak strength of the photons, extra care may be needed to reduce soft-tissue attenuation. For patients over 300 pounds in weight, the average table weight limit, it may not be possible to do lower back/hip measurements. The alternative is to do distal forearm/wrist measurements. NOTE Usual analysis includes averaging anterior-posterior image values taken from the L2 L4 vertebrae. Studies include bone density (of trabecular and cortical bone), bone mineral content, percent fat, and lean body mass. The lifetime risk to women for hip fracture is 15%, compared with men, 5%. Vertebral fractures usually occur earlier and carry with them pain, decreased physical activity, and change in physical appearance, e.g., reduced height and dowager s hump or senile dorsal kyphosis. With the treatment available, the earlier the diagnosis of osteopenia or osteoporosis, the more likely the better outcome. SPA and SEXA work extremely well for pediatric patients in determining bone density and mineral content of the radius by comparing values with published normal tables. 19

10766-04_CH04_redo.qxd 12/3/07 3:47 PM Page 20 NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference DEXA delivers improved precision (<1%) because of increased photon flux of x-rays (35 and 70 kev), greater stability, and constancy of the photon source and hence at present is considered the superior system for measuring bone density. Scan time is 4 minutes for lumbar spine with whole-body bone mineral content studies in 10 20 minutes (multiple detectors). These systems can also perform ROI studies on any bone in the body, opening application possibilities to a wide variety of orthopedic and metabolic studies not easily accommodated by other modalities. DPA may soon surpass 1% precision as well because of refinements in equipment. Both deliver clinically useful data and both deliver low radiation exposure (1 2 mrem to the skin surface). If 153 Gd is used as the gamma source (44 and 100 kev), although the useful life might be up to 18 months, it is recommended that it be changed once a year. CT can also be used for single or dual photon technique. The scanner can be programmed or modified to accommodate either. The radiation exposure, however, is 250 1000 mrem per study. Some of the positions required are awkward to achieve. Drugs for osteoporosis: Estrogen therapy and Hormone therapy (e.g., Prempro ) Raloxifene (Evista ) Teriparatide (parathyroid hormone, Forteo ) Alendronate (Fosamax ) Risedronate (Actonel ) Calcitonin (Miacalcin, Calcimar, or Fortical ) Pamidronate (Aredia ) Ibandronate (Boniva ) Corticosteroids Etidronate (Didronel ) Sodium fluoride (Fluoritab, Karidium, Pharmaflur ) PATIENT HISTORY The patient should answer the following questions. Do you have a history or family history of cancer? Y N If so, what type and for how long? What is your age, height, and weight? Do you have a history of bone disease? Y N Is there a family history of osteoporosis or dowager s hump? Y N Do you have any breaks or fractures? Y N Have you had any recent surgery requiring metal or screws in back, Y N hip, legs, or arms? Have you had any recent trauma to arms, hips, or legs? Y N If so, where and when? Y N Are you on steroid therapy? Y N Are you taking calcium supplements? Y N (continued) 20

10766-04_CH04_redo.qxd 12/3/07 3:47 PM Page 21 Chapter 4 Bone Density (Densitometry) Are you taking Didronel or alendronic sodium (Fosamax ) or Y N any drug for osteoporosis? If so, for how long? Do you have any prostheses? Y N Have you had any recent barium studies? Y N Have you had any of the following diseases: rheumatoid arthritis, Y N lupus, hyperthyroidism, hypothyroidism, kidney disease, diabetes, Cushing s syndrome, Crohn s disease, colitis, gastrectomy? Are you physically inactive? Y N Have you had any recent related studies or scans? Y N Female patients: Are you pregnant or nursing? Y N When was your last menstrual cycle? Have you experienced a pregnancy? Y N Have you experienced menopause? Y N If so, at what age? Have you had your ovaries removed? Y N Have you had a hysterectomy? Y N Are you on any female hormone replacement therapy? Y N Other department-specific questions. Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study? Suggested Readings Brener T, ed. Nursing 2007 Drug Handbook, 27th ed. Philadelphia: Lippincott Williams & Wilkins, 2006. Chohan N, ed. Nursing 99 Drug Handbook. Springhouse, PA: Springhouse, 1999. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998. 21

10766-04_CH04_redo.qxd 12/3/07 3:47 PM Page 22 NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference Notes 22